Global Search | Novartis

Sort by

Relevance

Newest first

Oldest first

Hide Filters

Showing 2756 results

Clinical Trials / Oct 16, 2025

Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis
Clinical Trials / Jun 29, 2025

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
Clinical Trials / Nov 26, 2025

Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
Press release / Dec 09, 2025

Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses

Ianalumab (9 mg/kg) plus eltrombopag extended ITP disease control by 45% with patients maintaining disease control 2.8 times longer than with placebo plus eltrombopag1,2 62% of patients treated with…
Clinical Trials / Jan 31, 2025

Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
Clinical Trials / May 16, 2024

Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent
Early careers
Event calendar
Press release / Dec 09, 2025

1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years

Progression-free response stayed consistent across age, BMI, and menopausal status in MONALEESA pooled analysis1 KISQALI is only CDK4/6i to demonstrate statistically significant overall survival (OS…
Biography / Aug 19, 2021

Karen Hale

‹ Previous page
1
…
15
16
17
18
19
20
21
…
276
› Next page